Rare or dysfunctional variants may impair AAT function despite ‘intermediate’ serum concentrations, while clinical modifiers—exacerbation burden, HRCT emphysema pattern/airway involvement, bronchiectasis/asthma overlap, and smoking history—can amplify neutrophil-driven inflammation beyond antiprotease capacity. The gene discussed is SERPINA1; the disease is asthma.